Sedana Medical receives additional patent for AnaConDa

The patent is central to the continued development of inhaled sedation. Launched in 2017, the AnaConDa-S has a dead space of 50 ml instead of 100 ml, as the first AnaConDa model. The goal is to reduce the dead space of AnaConDa-S by 20 percent down to 40 ml. A reduction in dead space for ventilated patients is always desirable in intensive care as it enables lung-protective ventilation compared with a higher dead space.

”Apart from the fact that we see great clinical benefits our patent protection is now being greatly strengthened. Eventual competitors or ordinary, passive HME filters will not be able to reduce their dead space with the help of inserts, without infringing on our new patent. For an innovation-driven company like Sedana Medical, patent protection is incredibly important,” said Christer Ahlberg, CEO of Sedana Medical.

The patent has been granted in Europe and Sedana Medical has also filed a patent application in the United States and in additional countries.

For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30
E-mail: christer.ahlberg@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company’s Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

The information was released for public disclosure, through the agency of the contact person above, on November 11, 2020 at 08:00 a.m. (CET).

About Sedana Medical

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa for the administration of volatile anaesthetics. Through a combination of AnaConDa and the candidate drug IsoConDa (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated intensive care patients. The company is working to obtain market approval in Europe for inhaled sedation in intensive care with the pharmaceutical IsoConDa® (isoflurane) during the second half of 2021.

Today, mechanically ventilated intensive care patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Based on an estimate of seven to eight million patients being sedated in intensive care due to mechanical ventilation globally, on average three to four days, Sedana Medical estimates the total market potential to SEK 20-30 billion, evenly distributed between the US, Europe and Asia. Three years after market approval in Europe Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent. The company has initiated a process to obtain market approval in the US in 2024. Registration activities have also been initiated in other markets outside the EU.

Sedana Medical has direct sales in the Nordic countries, Germany, Benelux, France, Great Britain and Spain as well as external distributors in parts of the rest of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.